Therapies for preventing heart failure

  • Richard F. Wright

Opinion statement

The prevalence of congestive heart failure is progressively increasing and despite recent advances in therapeutics, there is a continuing need for novel effective therapies. New, investigational treatment strategies include inotropic drugs, neurohormonal antagonists, anticytokine and anti-inflammatory strategies, hormonal therapies, and nutritional supplements. Current positive inotropes (eg, dobutamine and phosphodiesterase inhibitors) provide symptomatic relief, but newer agents may have a better adverse effect profile. Angiotensin-converting enzyme (ACE) inhibitors should remain first-line treatment with angiotensin receptor blockers used in ACE inhibitor-intolerant patients. Many new neurohormonal antagonists have recently been investigated and eplerenone has demonstrated clinical benefit. New hormonal, anticytokine, and anti-inflammatory therapies have shown benefit in small trials, but results in larger trials have been disappointing. Other approaches are currently being tested in large trials that will clarify their role. Nutritional supplements need to be tested in a large prospective trial before they can be recommended.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Jong P, Vowinckel E, Liu P, et al.: Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002, 162:1689–1694.PubMedCrossRefGoogle Scholar
  2. 2.
    Cowie MR, Wood DA, Coats AJ, et al.: Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000, 83:505–510.PubMedCrossRefGoogle Scholar
  3. 3.
    American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.Google Scholar
  4. 4.
    Maniolo TA, Baughmnan KL, Rodeheffer R, et al.: Prevalence and etiology of idiopathic dilated cardiomyopathy. Am J Cardiol 1992, 69:1458–1466.CrossRefGoogle Scholar
  5. 5.
    Tavazzi L, Opasich C: Clinical epidemiology of heart failure. Congest Heart Fail 1999, 5:260–269.PubMedGoogle Scholar
  6. 6.
    Gillum RF: Epidemiology of heart failure in the United States. Am Heart J 1993, 126:1042–1047.PubMedCrossRefGoogle Scholar
  7. 7.
    Lloyd-Jones DM, Larson MG, Leip EP, et al.: Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002, 106:3068–3072. The pivotal Framingham epidemiologic investigations have contributed greatly to our current understanding of the risk factors for cardiovascular disease, and this paper continues in that vein.PubMedCrossRefGoogle Scholar
  8. 8.
    Lakatta EG, Levy D: Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part II: the aging heart in health: links to heart disease. Circulation 2003, 107:346–354.PubMedCrossRefGoogle Scholar
  9. 9.
    Kitzman DW, Gardin JM, Gottdiener JS, et al.: Importance of heart failure with preserved systolic function in patients ≥ 65 years of age: CHS Research Group Cardiovascular Health Study. Am J Cardiol 2001, 87:413–419.PubMedCrossRefGoogle Scholar
  10. 10.
    Davies MK, Hobbs FDR, Davis RC, et al.: Prevalence of left ventricular systolic dysfunction and heart failure in the general population: main findings from the ECHOES (echocardiographic heart of England screening) study. Lancet 2001, 358:439–455.PubMedCrossRefGoogle Scholar
  11. 11.
    Redfield MM, Jacobsen SJ, Burnett JC, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194–202.PubMedCrossRefGoogle Scholar
  12. 12.
    McDonagh TA, Morrison CE, Lawrence A, et al.: Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet 1997, 350:829–833.PubMedCrossRefGoogle Scholar
  13. 13.
    Vasan RS, Larson MG, Benjamin EJ, et al.: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999, 33:1948–1955.PubMedCrossRefGoogle Scholar
  14. 14.
    Mosterd A, Hoes AW, de Bruyne MC, et al.: Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 1999, 20:447–455.PubMedCrossRefGoogle Scholar
  15. 15.
    Kenchiah S, Evans JC, Levy D, et al.: Obesity and the risk of heart failure. New Engl J Med 2002, 347:305–313.CrossRefGoogle Scholar
  16. 16.
    Levy D, Larson MG, Vasan RS, et al.: The progression from hypertension to congestive heart failure. JAMA 1996 275:1557–1562.PubMedCrossRefGoogle Scholar
  17. 17.
    He J, Ogden LG, Bazzano LA, et al.: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001, 161:996–1002.PubMedCrossRefGoogle Scholar
  18. 18.
    Slama M, Susic D, Frohlich E: Prevention of hypertension. Curr Opin Cardiol 2002, 17:531–536.PubMedCrossRefGoogle Scholar
  19. 19.
    Whelton PK, He J, Appel LJ, et al.: Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 2002, 288:1882–1888. An important summation of the “state of the art” in nonpharmacologic means to avoid the development of hypertension.PubMedCrossRefGoogle Scholar
  20. 20.
    Kostis JB, Davis BR, Cutler J. et al.: Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997, 278:212–216.PubMedCrossRefGoogle Scholar
  21. 21.
    Effects of an angiotensin-converting enzyme inhibitor, ramapril, on cardiovascular events in high-risk patients. Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. N Engl J Med 2000, 342:134–153.Google Scholar
  22. 22.
    Moser M, Hebert PR: Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996, 27:1214–1218.PubMedCrossRefGoogle Scholar
  23. 23.
    Davis BR, Cutler JA, Furberg CD, et al.: Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Ann Intern Med 2002, 137:313–320. Compelling evidence that not all antihypertensive therapies are equivalent in terms of patient outcomes.PubMedGoogle Scholar
  24. 24.
    Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [no authors listed]. JAMA 2002, 288:2981–2997. Further evidence that drug choice makes a difference, in the largest antihypertensive trial ever undertaken.Google Scholar
  25. 25.
    Whelton SP, Chin A, Xin X, He J: Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002, 136:493–503.PubMedGoogle Scholar
  26. 26.
    Levy WC, Cerqueira MD, Abrass IG, et al.: Endurance exercise training augments diastolic filling at rest and during exercise in healthy young and older men. Circulation 1993, 88:116–126.PubMedGoogle Scholar
  27. 27.
    Mokdad AH, Ford ES, Bowman BA, et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76–79.PubMedCrossRefGoogle Scholar
  28. 28.
    Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288:1723–1727.PubMedCrossRefGoogle Scholar
  29. 29.
    Freedman DS, Khan LK, Serdula MK, et al.: Trends and correlates of class 3 obesity in the United States form 1990 through 2000. JAMA 2002, 288:1758–1761.PubMedCrossRefGoogle Scholar
  30. 30.
    Kannel WB, D’Agostino RB, Siblershatz H, et al.: Profile for estimating risk of heart failure. Arch Intern Med 1999, 159:1197–1204.PubMedCrossRefGoogle Scholar
  31. 31.
    Chen Y-T, Vaccarino V, Williams CS, et al.: Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999, 106:605–612.PubMedCrossRefGoogle Scholar
  32. 32.
    Yancy WE, Westman EC, French PA, Califf RM: Diets and clinical coronary events: the truth is out there. Circulation 2003, 107:10–16. Well-written synopsis of the importance that diet plays in the development of atherosclerosis, from authors unafraid to stir up the status quo.PubMedCrossRefGoogle Scholar
  33. 33.
    Hu FB, Willett WC: Optimal diets for prevention of coronary heart disease. JAMA 2002, 288:2569–2578.PubMedCrossRefGoogle Scholar
  34. 34.
    Fox KF, Cowie MR, Wood DA, et al.: Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001, 22:228–236.PubMedCrossRefGoogle Scholar
  35. 35.
    Arnold JM, Yusuf S, Young J, et al.: Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003, 107:1278–1284. The first trial, and most influential to date, supporting use of ACE inhibition to prevent cardiovascular events, including the development of heart failure.CrossRefGoogle Scholar
  36. 36.
    Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [no authors listed]. N Engl J Med 1992, 327:685–691.Google Scholar
  37. 37.
    Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992, 327:669–677.PubMedCrossRefGoogle Scholar
  38. 38.
    Kober L, Torp-Pedersen C, Carlsen JE, et al.: A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril cardiac evaluation (TRACE) study group. N Engl J Med 1995, 333:1670–1676.PubMedCrossRefGoogle Scholar
  39. 39.
    Dries DL, Strong MH, Cooper RS, Drazner MH: Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002, 40:311–317.PubMedCrossRefGoogle Scholar
  40. 40.
    Vautrimpout R, Rouleau J, Wu C-C, et al.: Additive beneficial effect of beta-blockers to angiotensin converting enzymes inhibiot in the survival and ventricular endpoint (SAVE) study. J Am Coll Cardiol 1997, 29:229–236.CrossRefGoogle Scholar
  41. 41.
    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [no authors listed]. N Engl J Med 1991, 325:293–302.Google Scholar
  42. 42.
    Hjalmarson A, Goldstein S, Fagerberg B, et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heat failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERITHF). JAMA 2000, 283:1295–1302.PubMedCrossRefGoogle Scholar
  43. 43.
    Packer M, Coates AJS, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658.PubMedCrossRefGoogle Scholar
  44. 44.
    The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial [no authors listed]. Lancet 1999, 353:9–13.Google Scholar
  45. 45.
    The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group [no authors listed]. N Engl J Med 1997, 336:525–533.Google Scholar
  46. 46.
    Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717.PubMedCrossRefGoogle Scholar
  47. 47.
    Cohn JN, Tognini G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. Valsartan Heart Failure Trial Investigators. N Engl J Med 2001, 345:1667–1675.PubMedCrossRefGoogle Scholar
  48. 48.
    Rose EA, Gelijns AC, Moskowitz AJ, et al.: Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345:1435–1443.PubMedCrossRefGoogle Scholar
  49. 49.
    Moss AJ, Zareba W, Hall J, et al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877–883.PubMedCrossRefGoogle Scholar
  50. 50.
    Cazeau S, Leclercq C, Lavergne T, et al.: Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001, 344:873–880.PubMedCrossRefGoogle Scholar
  51. 51.
    Vasan RS, Benjamin EJ, Larson MG, et al.: Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA 2002, 288:1252–1259.PubMedCrossRefGoogle Scholar
  52. 52.
    McDonagh TA, Robb SD, Murdoch SR, et al.: Biochemical detection of left ventricular dysfunction. Lancet 1998, 351:9–13.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Richard F. Wright
    • 1
  1. 1.Pacific Heart InstituteSanta MonicaUSA

Personalised recommendations